ID

22204

Beschreibung

Study part: Treatment discontinuation report. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Stichworte

  1. 22.05.17 22.05.17 -
Rechteinhaber

Roche

Hochgeladen am

22. Mai 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

TREATMENT DISCONTINUATION REPORT Roche H0650g Breast Cancer

TREATMENT DISCONTINUATION REPORT

TREATMENT DISCONTINUATION REPORT
Beschreibung

TREATMENT DISCONTINUATION REPORT

Alias
UMLS CUI-1
C0677162
DATE OF DISCONTINUATION:
Beschreibung

therapy end date

Datentyp

date

Alias
UMLS CUI [1]
C1531784
CHECK THE PRIMARY REASON FOR DISCONTINUATION OF THERAPY:
Beschreibung

Primary Reason Therapy discontinuation

Datentyp

text

Alias
UMLS CUI [1]
C1549995
UMLS CUI [2]
C0677162
PROVIDE ADDITIONAL DETAILS FOR THE REASON(S) FOR STUDY DISCONTINUATION:
Beschreibung

Reason Therapy discontinuation

Datentyp

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0677162
I HAVE PERSONALLY REVIEWED THIS CASE REPORT FORM BOOK FOR COMPLETENESS AND ACCURACY OF ALL DATA RECORDED.
Beschreibung

consent

Datentyp

boolean

Alias
UMLS CUI [1]
C1511481
SIGNATURE OF INVESTIGATOR (M.D.)
Beschreibung

SIGNATURE OF INVESTIGATOR

Datentyp

text

Alias
UMLS CUI [1]
C2346576
DATE:
Beschreibung

DATE

Datentyp

date

Alias
UMLS CUI [1]
C0011008

Ähnliche Modelle

TREATMENT DISCONTINUATION REPORT

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
TREATMENT DISCONTINUATION REPORT
C0677162 (UMLS CUI-1)
therapy end date
Item
DATE OF DISCONTINUATION:
date
C1531784 (UMLS CUI [1])
Item
CHECK THE PRIMARY REASON FOR DISCONTINUATION OF THERAPY:
text
C1549995 (UMLS CUI [1])
C0677162 (UMLS CUI [2])
Code List
CHECK THE PRIMARY REASON FOR DISCONTINUATION OF THERAPY:
CL Item
ADVERSE EVENT/ INTERCURRENT ILLNESS (PLEASE RECORD ON ADVERSE EVENTS FORM)  (1)
C0877248 (UMLS CUI-1)
CL Item
LABORATORY ABNORMALITY (PLEASE DOCUMENT THE ABNORMALITY ON THE ADVERSE EVENTS PAGE) (2)
C0438215 (UMLS CUI-1)
CL Item
PATIENT REQUESTED REMOVAL FROM STUDY  (3)
CL Item
NON-COMPLIANCE (INCLUDING 3 CONSECUTIVEL Y MISSED rhuMAb HER2 INFUSIONS)  (4)
C0457432 (UMLS CUI-1)
CL Item
PATIENT DIED (COMPLETE DEATH REPORT FORM)  (5)
C0421611 (UMLS CUI-1)
CL Item
DISEASE PROGRESSION (INCLUDING METASTATIC BRAIN DISEASE)  (6)
C0242656 (UMLS CUI-1)
CL Item
LOST TO FOLLOW-UP  (8)
C1302313 (UMLS CUI-1)
CL Item
IMMUNOTHERAPY, CHEMOTHERAPY, HORMONAL THERAPY, OR RADIOTHERAPY DIRECTED AT THE TREATMENT OF EVALUABLE LESIONS=TREATMENT OF EVALUABLE LESIONS (24)
C0021083 (UMLS CUI-1)
C0392920 (UMLS CUI-2)
C0279025 (UMLS CUI-3)
C1522449 (UMLS CUI-4)
Reason Therapy discontinuation
Item
PROVIDE ADDITIONAL DETAILS FOR THE REASON(S) FOR STUDY DISCONTINUATION:
text
C0392360 (UMLS CUI [1,1])
C0677162 (UMLS CUI [1,2])
consent
Item
I HAVE PERSONALLY REVIEWED THIS CASE REPORT FORM BOOK FOR COMPLETENESS AND ACCURACY OF ALL DATA RECORDED.
boolean
C1511481 (UMLS CUI [1])
SIGNATURE OF INVESTIGATOR
Item
SIGNATURE OF INVESTIGATOR (M.D.)
text
C2346576 (UMLS CUI [1])
DATE
Item
DATE:
date
C0011008 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video